Moderna

RaySecur and Moderna Security Partnership Named Finalist for OSPA Award

Retrieved on: 
Wednesday, September 6, 2023
Partnership, Market intelligence, SAFETY, Law enforcement, DHS, EOD, ASIS International, ASIS, GSX, Security (finance), Online shopping, Moderna

BOSTON, Sept. 6, 2023 /PRNewswire/ -- RaySecur®, the leading provider of T-ray security imaging technology, is announcing that the award committee for the Outstanding Security Performance Awards (OSPAs) has selected RaySecur and its partner Moderna® as a finalist for an Outstanding Security Partnership award. To be considered, a company must demonstrate how the partnership resulted in clear, sustainable business benefits and a positive performance impact.

Key Points: 
  • After partnering with RaySecur, Moderna bolsters its security posture as recognized by the Outstanding Security Performance Awards.
  • BOSTON, Sept. 6, 2023 /PRNewswire/ -- RaySecur® , the leading provider of T-ray security imaging technology, is announcing that the award committee for the Outstanding Security Performance Awards (OSPAs) has selected RaySecur and its partner Moderna® as a finalist for an Outstanding Security Partnership award.
  • ASIS OSPAs recognize RaySecur as a finalist for the Outstanding Security Partner award.
  • RaySecur was selected to deploy its new T-ray security screening technology and develop security protocols for the biotech's global environment.

Pharmaceutical Temperature-Controlled Packaging Market, 2028 - Pharma TCP Market Digitization to Cut Costs and Streamline Processes - ResearchAndMarkets.com

Retrieved on: 
Monday, September 4, 2023
Packaging, Pharmaceutical, Health, Manufacturing, Vaccine, PCM, Research report, Pfizer, Pharmaceutical marketing, Dry ice, TCP, COVID-19, Intelligence, Temperature, COVID, FedEx, Patent, Biophysical environment, Growth, ESG, Johnson & Johnson, PCM, Inc., Lithium, Medical device, Electric battery, Pharmaceutical industry, Retail, Moderna

Pharmaceutical Temperature-Controlled Packaging Market is projected to reach a value of $16.8 billion by 2028 from $10.6 billion in 2023, growing at a CAGR of 9.5%.

Key Points: 
  • Pharmaceutical Temperature-Controlled Packaging Market is projected to reach a value of $16.8 billion by 2028 from $10.6 billion in 2023, growing at a CAGR of 9.5%.
  • This research report incorporates an in-depth analysis of the global temperature-controlled packaging market, including market estimates and trends through 2028.
  • Major players, competitive intelligence, innovative technologies, market dynamics, sustainability in the cold chain, and market opportunities are discussed in detail.
  • Temperature-controlled packaging (TCP) is created and validated by strict requirements to maintain products within a particular temperature range for a predetermined amount of time.

Global Quantum Computing in Healthcare Market 2023-2030: Unleashing Quantum Power - Transforming Cancer Treatment through Quantum Computing - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 31, 2023
Oncology, Data Management, Health, Technology, Health Technology, Software, Biotechnology, IBM, Component, Partnership, Radiation, Therapy, Genetics, Bayer, Personalized medicine, Moderna, Messenger, Compound annual growth rate, Radiation therapy, Traction, TensorFlow, Investment, Application, Hardware, Drug discovery, Deployment, Quantum, Pharmaceutical industry, Medical imaging, Television

In 2022, the radiotherapy segment within the quantum computing in the healthcare market garnered $5,335.2 million in revenue.

Key Points: 
  • In 2022, the radiotherapy segment within the quantum computing in the healthcare market garnered $5,335.2 million in revenue.
  • Based on comprehensive analysis, Google LLC emerged as a prominent frontrunner in quantum computing in the healthcare market.
  • Quantum computing in the healthcare market faces challenges related to the high implementation costs and accuracy issues associated with quantum computing systems.
  • Quantum computing is gaining significant traction in the healthcare sector, shaping innovative solutions to address complex challenges and optimize healthcare processes.

UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings

Retrieved on: 
Monday, August 14, 2023
Vaccine, Infection, YWCA, MRNA, Pediatrics, University of Massachusetts, Therapy, YWCA of Central Massachusetts, Community advisory board, Cytomegalovirus, Education, Hearing loss, Parent, Biotechnology, Drug, Medicine, Research, RNA, Messenger, Groundnut rosette virus, Stoddard, Central Massachusetts, Risk, Child, CMV, Microcephaly, Pregnancy, Birth, MPH, Developmental disability, Tutoring, Nursing, MD, Moderna

WORCESTER, Mass., Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV) transmission. The study is a collaboration with Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)-based therapeutics and vaccines, which is currently researching a vaccine for CMV.

Key Points: 
  • WORCESTER, Mass., Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV) transmission.
  • The study, called CMV Transmission and Immune Tracking (CMVTransmIT), will examine how CMV spreads among children and between household members, with an aim to characterize immune responses to CMV infection over time.
  • Findings from the study will inform the design of CMV prevention strategies, including awareness campaigns for CMV, to potentially reduce its spread in similar group settings.
  • "Dr. Gibson's CMV Transmit study is an important effort to provide a better understanding of CMV transmission dynamics and immune response to infection."

Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

Retrieved on: 
Wednesday, July 5, 2023
Vaccine, Biologics license application, MRNA, Urinary tract infection, Therapy, Public, Biotechnology, European Medicines Agency, Cancer, Therapeutic Goods Administration, Licensure, RNA, Messenger, EMA, RSV, European, Ageing, TGA, FDA, ARD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Disease, Pharmaceutical industry, Moderna, Swissmedic

The ConquerRSV study is ongoing, and additional efficacy analyses are planned as cases accrue, including for severe RSV.

Key Points: 
  • The ConquerRSV study is ongoing, and additional efficacy analyses are planned as cases accrue, including for severe RSV.
  • In addition to older adults, mRNA-1345 is being investigated in a fully enrolled, ongoing Phase 1 trial in pediatric populations.
  • Moderna's respiratory disease vaccine pipeline includes Phase 3 trials against influenza and a next-generation COVID-19 candidate.
  • The pipeline also includes four additional influenza vaccines with expanded antigens, vaccines against other respiratory pathogens, and five combination vaccine programs.

Investing ‘Summer Vibes’ Drives Interest in Cruise and AI Stocks, According to New Apex Q2 2023 Investor Study

Retrieved on: 
Thursday, August 10, 2023
Personal Finance, Finance, Fintech, Millennials, Professional Services, Generation Z, Baby Boomers, Data Analytics, Consumer, Generation X, META, Carnival Corporation & plc, MRNA, First Republic Bank, Baby boomers, Gen, CCL, AMD, SOFI, Cruise line, Generation, NVDA, TSLA, AMZN, Multimedia, Movement, Norwegian Cruise Line, Apex, AAPL, Royal Caribbean Group, PLTR, Investment, RCL, MSFT, NCLH, Cryptocurrency, Financial adviser, Dairy, Q2, Nvidia, Moderna, AI

With summer travel booming, all four generations - Gen Z, Millennials, Gen X and Boomers - invested heavily in popular cruise lines in Q2, according to the Q2 2023 Apex Next Investor Outlook (ANIO).

Key Points: 
  • With summer travel booming, all four generations - Gen Z, Millennials, Gen X and Boomers - invested heavily in popular cruise lines in Q2, according to the Q2 2023 Apex Next Investor Outlook (ANIO).
  • The study utilizes data from Apex Fintech Solutions (“Apex”), the fintech for fintechs powering innovation and the future of digital wealth management.
  • The data also reinforced the continued powerful interest in AI, with major rallies and investments in Nvidia, C3 AI, and Palantir.
  • The following data refers to the rankings of the most commonly held securities at Apex by generation in Q2 2023.

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

Retrieved on: 
Monday, July 24, 2023
SAB, Precision BioSciences, CRISPR, Biotechnology, R&D, Therapy, Senior, Hematology, Cardiovascular Cell Therapy Research Network, Gene editing, Clinical trial, Cancer, DRS, MBA, RNA, Messenger, Precision, Chakraborty, Patient, Moderna, Cell, CRISPR Therapeutics, DSM-IV codes, Vaccine, Pharmaceutical industry, Antibiotics, Specific, Research

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, July 24, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D. to its scientific advisory board (SAB).
  • Chakraborty and Nicholson join the SAB," said Brent Stead, Ph.D., MBA, CEO of Specific "Their expertise will be incredibly valuable as we advance our Dualase® gene editors toward the clinic.
  • "The Specific team is tackling areas of acute medical need where Dualase gene editors would be well differentiated from existing treatments."

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

Retrieved on: 
Wednesday, July 19, 2023
Nucleus, GSK plc, Amgen, Medical Affairs Bureau, University, Senior, ALL, Belimumab, Bone marrow, Wharton School of the University of Pennsylvania, Trastuzumab/hyaluronidase, Roche, Haemophilia, Human Genome Sciences, MBA, SLE, AstraZeneca, Bachelor of Science, Veronica, ASCO, Faculty of Medical Sciences, University of Buenos Aires, CDMO, Acquisition, Project management, Partner, Patient, Regeneron Pharmaceuticals, Engineering, Moderna, Hematology, CFO, SVP, Trastuzumab emtansine, Therapy, Stomach, BLA, HGS, Ionis Pharmaceuticals, Management, Pharmaceutical industry, West Virginia University

LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert F. Dolski as Chief Financial Officer (CFO), effective August 7, 2023.

Key Points: 
  • Mr. Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as Chief Financial Officer at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. in 2022.
  • Mr. Dolski will succeed Dr. Lucinda Crabtree, who, as previously announced, will be leaving Autolus in August.
  • Veronica joined Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer.
  • Veronica joins Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer.

Science Exchange Hires Veteran Enterprise Technology Leader Ander Tallett as Chief Strategy Officer

Retrieved on: 
Monday, July 17, 2023
Research, Technology, Medical Supplies, Software, Practice Management, Biotechnology, Health, Data Management, Science, Other Science, Science Exchange (company), Organization, Growth, Entrepreneurship, Exchange, Multimedia, ERP, ELN, CSO, Management, Moderna

Science Exchange , the first purchasing and supplier orchestration platform for life sciences, is thrilled to announce the appointment of former Moderna Executive Ander Tallett as its Chief Strategy Officer (CSO).

Key Points: 
  • Science Exchange , the first purchasing and supplier orchestration platform for life sciences, is thrilled to announce the appointment of former Moderna Executive Ander Tallett as its Chief Strategy Officer (CSO).
  • View the full release here: https://www.businesswire.com/news/home/20230717911008/en/
    As CSO, Tallett will lead corporate and product strategy, opening an exciting chapter for Science Exchange.
  • Tallett said, "Joining Science Exchange at this pivotal moment is exciting.
  • Science Exchange stands uniquely prepared with its technology to profoundly simplify and automate critical functions such as purchasing, supplier management, and payment processing."

MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE

Retrieved on: 
Thursday, June 29, 2023
Vaccine, MRNA, NDS, Therapy, SARS-CoV-2, Biotechnology, COVID-19, RNA, Messenger, Moderna, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, XBB

TORONTO, June 29, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA-1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2.

Key Points: 
  • TORONTO, June 29, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA-1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2.
  • An updated vaccine will ensure Canadians have the most current and effective option to keep them protected.
  • We have initiated our submission with Health Canada and, pending approval, will be ready to supply an XBB monovalent vaccine in time for the fall," said Patricia Gauthier, President and General Manager, Moderna Canada.
  • Additionally, Moderna has generated preliminary clinical data of its monovalent XBB.1.5 vaccine candidate showing an immune response against XBB descendent sublineages such as XBB.1.5, XBB.1.16, and XBB.2.3.2.